Before IRB Submission: How to Plan Clinical Trial Ads That Patients Respond To
An institutional review board (IRB) can approve every word of a clinical trial ad, and the ad can still fail. Approval confirms the ad is fair and not coercive. It says nothing about whether the right patients will read it, respond and qualify.
That gap costs more than most study teams expect. Changing recruitment copy after IRB approval may require further IRB review before the revised version can run. A message that underperforms early in patient recruitment can create avoidable delays before a stronger version reaches patients.
Why recruitment ads get so much IRB attention
The U.S. Food and Drug Administration (FDA) treats direct advertising for study participants as the start of the informed consent process. That is why the IRB reviews the ad itself, not only the protocol.
Under FDA guidance, the IRB:
- Reviews the final printed copy, including type size and other visual effects
- Reviews the final audio or video for broadcast ads
- May treat an ad added after initial approval as an amendment to the ongoing clinical trial
FDA also expects an ad to include only what a prospective participant needs to judge eligibility and interest.
For the full checklist, see Clinical trial advertising guidelines to follow for IRB submission.
Approval and performance are different tests
Two ads can follow every rule above and perform very differently. The difference usually comes from choices that sit well inside the guidelines:
- How the ad names the condition: the clinical term, or the words patients use
- Which eligibility criteria appear in the ad, and which wait for the screener
- What the ad asks the patient to do next
In several of Antidote's feasibility tests, a single creative or message variant generated 60% to 90% of all qualified leads. When one variant carries most of the results, choosing the message early matters.
What a feasibility test shows
One Antidote test ran for four days for an obesity medication-switch study. To qualify, patients had to be on a weight-management medication at a stable dose for a set period, with documented weight loss.
Interest was high, but treatment-history requirements disqualified most respondents. The test separated two problems that look identical in a slow enrollment report: a message that doesn't attract patients, and criteria that screen out patients who do respond.
How to prepare clinical trial ads before IRB submission
- Start with message research, not patient recruitment.
With input from your compliance team, use non-recruitment research, such as feasibility research, patient advisory input or concept interviews, to learn how patients describe their condition and where study criteria cause drop-off. Your compliance team should confirm whether your IRB needs to review the research materials.
- Draft two or three ad variants that already meet FDA guidance.
Change one element at a time (the condition name, the headline or the image) so the study team can see which change made the difference.
- Check each variant against a screener built from the draft protocol.
That way the study team plans around who is likely to qualify, not only who is likely to click.
- Find where patients are likely to drop out,
At the ad, the landing page or a specific screener question.
- Submit the variants together in your IRB package.
Along with the screener logic. If the IRB approves more than one variant, the study team can compare them once patient recruitment begins, within what the IRB approved.
Frequently asked questions
Do clinical trial ads need IRB approval?
Under FDA guidance, direct advertising for participants should be reviewed and approved by the IRB, usually in the initial review package. Clinical trial listings limited to basic information, such as title, purpose, eligibility and contact details, do not need separate approval.
Can you change a recruitment ad after IRB approval?
Yes, but the change may require further IRB review, often as an amendment. When the new ad is easy to compare with the approved consent document, the IRB may approve it through expedited review.
What should a clinical trial ad leave out?
Claims of safety or effectiveness, comparisons with other treatments, "new treatment" without saying it is investigational, "free medical treatment" and emphasis on payment.
Test the message before the IRB locks it in
Antidote runs short feasibility tests that show how real-world audiences respond to your draft protocol and patient-facing messaging before patient recruitment begins. You’ll see which messages draw qualified interest and which eligibility criteria hold enrollment back, while there is still time to refine both before IRB submission.
